Abstract
Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.
| Original language | English |
|---|---|
| Article number | 948348 |
| Journal | Frontiers in Oncology |
| Volume | 13 |
| DOIs | |
| State | Published - Jan 24 2023 |
Bibliographical note
Publisher Copyright:Copyright © 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland.
Funding
This research was supported by an NCI grant (P30 CA177558) which supports the Biospecimen Procurement & Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center.
| Funders | Funder number |
|---|---|
| National Childhood Cancer Registry – National Cancer Institute | P30 CA177558 |
| National Childhood Cancer Registry – National Cancer Institute | |
| University of Kentucky Markey Cancer Center |
Keywords
- HER2/neu
- radiopharmaceutical
- triage
- uterine cervical adenocarcinoma
- uterine cervical cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
